Korea Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also explains his decision to focus on manufacturing oligonucleotides, the potential in that market, and the challenges to the next objectives.…
Korea Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the moment the main concern is that Korean prices are too low Could you provide our readers with an introduction to…
Korea Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights into opportunities that exist in the Korean market and explains why Korea need not follow the Swiss model in its…
Korea National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of oncology therapies, we still need to assist in the development of local Korean biotech companies. — Young-Whan Park, President of National…
Korea Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech firms in Korea within three years. We are at a critical juncture. If we fail to catch up with…
Korea Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine. Dr Park also provides his assessment of Korea’s challenge in commercialising its academic research. NOV not only supports research…
Korea Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future trading relationship between the two economic powerhouses. Multinational pharmaceutical corporations demand more patient access and the abolition of the…
South Korea Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This surprising move towards legalisation is intended to expand treatment options for patients suffering from rare diseases such as epilepsy. …
Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…
Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…
Korea Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the potential implications for the US-Korea FTA renegotiations. The rate [of ageing] in Korea is actually even more serious than…
South Korea South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022 and pledges to expand healthcare coverage to cover 70 percent of the people’s costs. Korea currently runs on a health…
See our Cookie Privacy Policy Here